Journal of Archives in Military Medicine

Published by: Kowsar

An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines

Alireza Tahamtan 1 , 2 , Javad Charostad 1 , Seyyed Javad Hoseini Shokouh 3 and Mohammad Barati 3 , *
Authors Information
1 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
3 Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Archives in Military Medicine: September 2017, 5 (3); e12315
  • Published Online: September 26, 2017
  • Article Type: Review Article
  • Received: April 30, 2017
  • Revised: September 3, 2017
  • Accepted: September 5, 2017
  • DOI: 10.5812/jamm.12315

To Cite: Tahamtan A, Charostad J, Hoseini Shokouh S J, Barati M. An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines, J Arch Mil Med. 2017 ; 5(3):e12315. doi: 10.5812/jamm.12315.

Abstract
Copyright © 2017, Journal of Archives in Military Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Conclusions
References
  • 1. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000; 18(15): 1436-47[DOI][PubMed]
  • 2. Bloom DE, Canningm D. , Weston M. The value of vaccination 2005;
  • 3. Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011; 3(1): 73-8[DOI][PubMed]
  • 4. Tahamtan A, Charostad J, Shokouh H, Javad S, Barati M. An overview of different types of immune stimulating adjuvants and their application. Paramedical Sci Mil Health. 2016; 11(3): 43-51
  • 5. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol. 2011; 11(10): 1464-88[DOI][PubMed]
  • 6. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol. 2005; 21(5): 244-9[DOI][PubMed]
  • 7. Ehreth J. The global value of vaccination. Vaccine. 2003; 21(7-8): 596-600[DOI][PubMed]
  • 8. Leung AKC. History of Vaccine Development. 2011; : 5-12
  • 9. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005; 18(1): 21-5[PubMed]
  • 10. Plotkin SA. History of vaccine development. 2011; [DOI]
  • 11. Wever PC, van Bergen L. Prevention of tetanus during the First World War. Med Humanit. 2012; 38(2): 78-82[DOI][PubMed]
  • 12. Rappuoli R, Malito E. Corynebacterium diphtheriae and Related Toxigenic Specie. 2014; : 225-38[DOI]
  • 13. Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine. 2008; 26(23): 2890-8[DOI][PubMed]
  • 14. Hoyt K. Vaccine innovation: lessons from World War II. J Public Health Policy. 2006; 27(1): 38-57[DOI][PubMed]
  • 15. Ehreth J. The value of vaccination: a global perspective. Vaccine. 2003; 21(27-30): 4105-17[DOI][PubMed]
  • 16. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol. 2007; 25(12): 1361-6[DOI][PubMed]
  • 17. Hilleman MR. History of Vaccine Development. 2011; : 207-18[DOI]
  • 18. Avery OT, Goebel WF. Chemo-Immunological Studies on Conjugated Carbohydrate-Proteins : V. The Immunological Specifity of an Antigen Prepared by Combining the Capsular Polysaccharide of Type Iii Pneumococcus with Foreign Protein. J Exp Med. 1931; 54(3): 437-47[DOI][PubMed]
  • 19. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs. 1998; 10(2): 137-58[DOI][PubMed]
  • 20. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185(1): 251-7[DOI][PubMed]
  • 21. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008; 9(10): 776-88[DOI][PubMed]
  • 22. Teimourpour R, Meshkat Z, Arzanlou M, Peeridogaheh H. DNA vaccine: The third generation vaccine [In Persian]. Qom Univ Med Sci J. 2016; 10(10): 86-99
  • 23. Goetz KB, Pfleiderer M, Schneider CK. First-in-human clinical trials with vaccines--what regulators want. Nat Biotechnol. 2010; 28(9): 910-6[DOI][PubMed]
  • 24. Han S. Clinical vaccine development. Clin Exp Vaccine Res. 2015; 4(1): 46-53[DOI][PubMed]
  • 25. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine. 2008; 26(52): 6759-67[DOI][PubMed]
  • 26. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect. 2004; 49(3): 179-209[DOI][PubMed]
  • 27. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005; 11(4 Suppl)-32[DOI][PubMed]
  • 28. Organization WH . Relevé épidémiologique hebdomadaire/Section d'hygiène du Secrétariat de la Société des Nations= Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. 2004; 79(4): 27
  • 29. Ravanfar P, Satyaprakash A, Creed R, Mendoza N. Existing antiviral vaccines. Dermatol Ther. 2009; 22(2): 110-28[DOI][PubMed]
  • 30. Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003; 63(19): 2107-26[DOI][PubMed]
  • 31. Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther. 2008; 8(8): 1177-85[DOI][PubMed]
  • 32. Mohebali M, Hajjaran H, Hamzavi Y, Mobedi I, Arshi S, Zarei Z, et al. Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet Parasitol. 2005; 129(3-4): 243-51[DOI][PubMed]
  • 33. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998; 351(9115): 1540-3[DOI][PubMed]
  • 34. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol. 2009; 16(12): 1709-19[DOI][PubMed]
  • 35. Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW. Epitope discovery and their use in peptide based vaccines. Curr Pharm Des. 2010; 16(28): 3149-57[DOI][PubMed]
  • 36. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009; 30(1): 23-32[DOI][PubMed]
  • 37. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001; 1(3): 273-86[DOI][PubMed]
  • 38. Baker PJ. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J Infect Dis. 1992; 165 Suppl 1-8[DOI][PubMed]
  • 39. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975; 56(6): 1536-47[DOI][PubMed]
  • 40. Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics. 1984; 74(5): 857-65[PubMed]
  • 41. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis. 1995; 21(3): 616-20[DOI][PubMed]
  • 42. Avery OT, Goebel WF. Chemo-Immunological Studies on Conjugated Carbohydrate-Proteins : Ii. Immunological Specificity of Synthetic Sugar-Protein Antigens. J Exp Med. 1929; 50(4): 533-50[DOI][PubMed]
  • 43. Ward J, Berkowitz C, Pescetti J, Burkart K, Samuelson O, Gordon L. Enhanced immunogenicity in young infants of a new Haemophilus influenzae type b (Hib) capsular polysaccharide (PRP)-diphtheria toxoid (D) conjugate vaccine. Pediatr Res. 1984; 18(287)
  • 44. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet. 1992; 340(8819): 592-4[DOI][PubMed]
  • 45. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005; 11(4 Suppl)-11[DOI][PubMed]
  • 46. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012; 45(12): 1102-11[DOI][PubMed]
  • 47. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 2014;
  • 48. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine. 2008; 26(14): 1709-24[DOI][PubMed]
  • 49. Borja-Cabrera GP, Santos FB, Nico D, Gravino AE, Manna L, Palatnik M, et al. The Leishmune®́s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia Vaccinol. 2012; 6: 64-73[DOI]
  • 50. Smillie C, Garcillan-Barcia MP, Francia MV, Rocha EP, de la Cruz F. Mobility of plasmids. Microbiol Mol Biol Rev. 2010; 74(3): 434-52[DOI][PubMed]
  • 51. Fındık, A. , Çiftci, A. . Bacterial DNA vaccines in veterinary medicine: A review. J Vet Adv. 2012; 2(4): 139-48
  • 52. Bins AD, van den Berg JH, Oosterhuis K, Haanen JB. Recent advances towards the clinical application of DNA vaccines. Neth J Med. 2013; 71(3): 109-17[PubMed]
  • 53. Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci. 2014; 21: 69[DOI][PubMed]
  • 54. Tahamtan A, Tabarraei A, Moradi A, Dinarvand M, Kelishadi M, Ghaemi A, et al. Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells. Artif Cells Nanomed Biotechnol. 2015; 43(6): 366-72[DOI][PubMed]
  • 55. Rappuoli R, Medaglini D. Big science for vaccine development. Vaccine. 2014; 32(37): 4705-7[DOI][PubMed]
  • 56. Tahamtan A, Char Ostad J, Behboudi E, Hoseini-Shokouh SJ, Barati M. Nanotechnology and Modern Medicine: The medical applications of nanotechnology [In Persian]. Nurse Phys Within War . 2016; 4(10): 80-90
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments